德赛诺替尼，CAS 登记号 944842-54-0，由济南圣和化工有限公司现货供应，可提供纯度 按批次COA提供(不公开发布) 的规格，下游主要用于医药中间体及原料药。支持样品与小批量试用，批量价格请联系我们获取，验收以批次 COA 为准。
医药中间体及原料药
每批随货提供 COA；可按需提供 MSDS 及技术文件。邮件注明产品名称与 CAS 号，一个工作日内回复报价。
本页已列出 德赛诺替尼 的 CAS 号：944842-54-0，可与随货 COA 核对。
常见纯度为 按批次COA提供(不公开发布)，包装形式为 按订单/批次确认(不公开发布)，特殊规格可在询价时说明。
主要涉及医药中间体及原料药。
来信 info@591daili.com 或 WhatsApp 联系，提供产品名称、CAS 号与数量，确认价格与交期后即可安排发货，验收以批次 COA 为准。
Decernotinib · CAS 944842-54-0 · C18H19F3N6O. UNII MZK2GP0RHK.
| CAS Registry Number | 944842-54-0 |
|---|---|
| PubChem CID | 59422203 |
| Molecular formula | C18H19F3N6O |
| IUPAC name | (2R)-2-methyl-2-[[2-(1H-pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-4-yl]amino]-N-(2,2,2-trifluoroethyl)butanamide |
| UNII (FDA) | MZK2GP0RHK |
| Molecular Weight | 392.4 |
|---|---|
| XLogP3 | 3.1 |
| Hydrogen Bond Donor Count | 3 |
| Hydrogen Bond Acceptor Count | 8 |
| Rotatable Bond Count | 6 |
| Exact Mass | 392.15724374 |
| Monoisotopic Mass | 392.15724374 |
| Topological Polar Surface Area | 95.6 |
| Heavy Atom Count | 28 |
| Formal Charge | 0 |
| Reported hazard statements | H302 (100%), H315 (100%), H319 (100%), H335 (100%) |
|---|
H302 (100%): Harmful if swallowed [Warning Acute toxicity, oral]
H315 (100%): Causes skin irritation [Warning Skin corrosion/irritation]
Decernotinib; 944842-54-0; Adelatinib; VX-509; VRT-831509; VX509; MZK2GP0RHK; VX 509; VRT 831509; DTXSID70241504; (2R)-2-methyl-2-[[2-(1H-pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-4-yl]amino]-N-(2,2,2-trifluoroethyl)butanamide; decernotinibum; (2R)-2-methyl-2-((2-(1H-pyrrolo(2,3-b)pyridin-3-yl)pyrimidin-4-yl)amino)-N-(2,2,2-trifluoroethyl)butanamide; RefChem:407157; DTXCID30163995; Decernotinib (VX-509)
CAS 944842-54-0; molecular formula C18H19F3N6O; molecular weight — g/mol.
Decernotinib, 944842-54-0, Adelatinib, VX-509, VRT-831509, VX509.
Hazard statements reported: H302, H315, H319, H335.
Facts on this page are taken from PubChem (US National Library of Medicine) and Wikidata. Grade-specific data — assay, moisture, particle size, packaging, shelf life — is issued per batch on the COA and is not published here.